March 9, 2018
Eisai CEO Haruo Naito stressed on March 8 that PIII trials being conducted with Biogen on Alzheimer’s hopeful aducanumab is “steadily ongoing,” noting that a 500-plus increase in their sample size has “no impact” on the odds of success of...read more